Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis.

In this paper, our aim was to systematically evaluate published evidence of bone fracture risk associated with tamoxifen and aromatase inhibitors in women aged 65 and under, and diagnosed with nonmetastatic breast cancer.